Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience, Inc. (NASDAQ: HBIO) is a life science tools company that develops, manufactures and sells technologies, products and services used in research, drug and therapy discovery, bio‑production and preclinical testing. News about Harvard Bioscience often centers on how its laboratory instruments and platforms support life science applications for academic institutions, government laboratories, pharmaceutical companies, biotechnology firms and contract research organizations.
Investors and researchers following HBIO news will find regular updates on quarterly financial results, including revenues, gross margins, net income or loss, adjusted EBITDA and cash flows from operations, as reported in the company’s earnings press releases. These announcements are typically accompanied by guidance ranges for upcoming quarters and commentary on demand trends, backlog and operational discipline.
Harvard Bioscience news also covers capital structure and financing developments. In 2025, the company reported amendments to its existing credit agreement, discussions with lenders, and the execution of a new Loan and Security Agreement with BroadOak that introduced term loans and a convertible term loan, along with associated warrants and board nomination rights. These items appear in both press releases and Form 8‑K filings and are relevant to readers tracking the company’s liquidity, debt profile and going‑concern considerations.
Another theme in HBIO coverage is corporate governance and leadership changes. The company has announced a CEO succession plan, the appointment of new independent directors, and the designation of a lead independent director. Additional news items describe board appointments linked to financing arrangements and changes in audit committee composition. Operational news has included expanded distribution agreements for laboratory equipment with a major scientific supplier and references to technologies such as pumps, spectrophotometers, BTX electroporation systems and Mesh MEA organoid platforms.
For readers interested in HBIO, this news stream provides context on the company’s financial performance, governance, listing status on Nasdaq, and its role in supplying tools for life science research and preclinical testing. Regular updates can help observers understand how Harvard Bioscience is managing its business and capital structure while serving global life science customers.
Harvard Bioscience (Nasdaq: HBIO) has updated shareholders on its strategic initiatives aimed at long-term growth, despite challenges posed by COVID-19. The company reported increased demand for research products related to the pandemic. Key strategic actions from September 2019 are on track, including a $6 million debt reduction, improved margins, and a streamlined manufacturing process. Harvard Bioscience also emphasizes efforts to support research organizations in developing COVID-19 treatments and vaccines. Overall, they remain committed to creating shareholder value as they navigate current challenges.
Harvard Bioscience (Nasdaq: HBIO) reported Q1 2020 revenue of $23.8 million, down 16% year-over-year due to the Covid-19 pandemic. The company experienced a gross margin of 54.6% but faced an operating loss of $3.3 million, compared to a loss of $0.1 million in Q1 2019. Adjusted loss per share was $(0.01), down from $0.02 in the previous year. Cash flow from operations was $2.9 million, with a $5 million debt reduction. The company has retracted its full-year 2020 guidance, anticipating a revenue decline of 20%-30% in Q2.